Enzyme replacement therapy offers hope for ultra-rare Hunter syndrome

Ongoing clinical research at UNC could lead to a first-of-its-kind enzyme replacement therapy for Hunter syndrome, an ...

Stratifying Risk in Sarcoidosis: Laryngeal vs Nodal Management

Systemic therapy for sarcoidosis is reserved for organ-threatening disease, and laryngeal involvement necessitates treatment ...
Healio

Oral Systemic Therapy for Psoriasis

Any practitioner who cares for patients with psoriasis should be familiar with and make use of systemic therapies. These medications are clearly indicated for patients who have diffuse disease where ...
BioWorld

Autologous B-cell therapy WFX-001 corrects systemic α-GAL enzyme deficiency in vivo

Walking Fish Therapeutics Inc. presented a new first-in-class autologous B-cell therapy, named WFX-001, being developed for the treatment of Fabry disease.
BioWorld

Autologous B-cell therapy WFX-001 corrects systemic α-GAL enzyme deficiency in vivo

Breaking News: Trump administration impacts continue to roil the life sciences sector Home » Autologous B-cell therapy WFX-001 corrects systemic α-GAL enzyme deficiency in vivo ...